ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Prognostic impact of weight loss during first-line chemotherapy in extensive-disease small cell lung cancer.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe adverse prognostic impact of cancer cachexia is well recognized. We aimed to evaluate the prognostic impact of weight loss during first-line platinum-based chemo(immuno)therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC).
methodsWe retrospectively reviewed 187 of 346 ED-SCLC patients (54%) treated between 2009 and 2021, and collected body weight at three time points: 6 months before, at the start of the first cycle, and at the beginning of the third cycle of initial chemotherapy. Based on pretreatment cachexia defined according to the Fearon criteria (weight loss > 5% or > 2% with BMI < 20 kg/m
resultsMedian overall survival (OS) differed significantly among the groups (p = 0.020), with the non-weight-loss group showing more favorable survival than the other groups (adjusted hazard ratios, 1.51-1.65; all p ≤ 0.05). The non-weight-loss group experienced fewer grade ≥ 2 anorexia and nausea/vomiting events during the first two cycles.
conclusionsIn patients with ED-SCLC, the absence of weight loss before and during chemotherapy was associated with longer OS and fewer gastrointestinal toxicities. These findings underscore the importance of early supportive care to prevent weight loss, including proactive management of gastrointestinal toxicities during chemotherapy.
Indexed as
Identifiers
42228208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.